Track topics on Twitter Track topics that are important to you
Boston Scientific Paclitaxel Eluting Self Expanding Stent System PubMed articles on BioPortfolio. Our PubMed references draw on over 21 million records from the medical literature. Here you can see the latest Boston Scientific Paclitaxel Eluting Self Expanding Stent System articles that have been published worldwide.
We have published hundreds of Boston Scientific Paclitaxel Eluting Self Expanding Stent System news stories on BioPortfolio along with dozens of Boston Scientific Paclitaxel Eluting Self Expanding Stent System Clinical Trials and PubMed Articles about Boston Scientific Paclitaxel Eluting Self Expanding Stent System for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Boston Scientific Paclitaxel Eluting Self Expanding Stent System Companies in our database. You can also find out about relevant Boston Scientific Paclitaxel Eluting Self Expanding Stent System Drugs and Medications on this site too.
The ION Study assessed clinical outcomes for the thin-strut, ION™ (TAXUS Element) Paclitaxel-Eluting Platinum Chromium Coronary Stent System (Boston Scientific, Marlborough, MA) in unselected patients.
The placement of a self-expandable metal stent (SEMS) is widely used in patients with unresectable malignant biliary obstructions, but SEMSs are susceptible to occlusion by tumor ingrowth or overgrowth. The efficacy and safety of a novel paclitaxel-eluting biliary metal stent incorporating sodium caprate (MSCPM-III) were compared prospectively with those of a covered metal stent (CMS) in patients with malignant biliary obstructions.
We aimed to test the hypothesis that presence of in-stent yellow plaque (YP) assessed by angioscopy would be a risk of very late stent failure (VLSF) of the cobalt chromium everolimus-eluting stent (CoCr-EES) in comparison with first-generation drug-eluting stents (DES).
Coronary drug-eluting stent development has introduced new metal alloys, changes in stent architecture and bioresorbable polymers. Whether these advancements improve long-term clinical safety and efficacy has been inconsistent in prior studies.
In this substudy of the SORT OUT VII trial, the clinical outcomes among patient with diabetes mellitus treated with Orsiro sirolimus-eluting stent (O-SES; Biotronik, Bülach, Switzerland) or Nobori biolimus-eluting stent (N-BES; Terumo, Tokyo, Japan) were compared.
Endothelial progenitor cells (EPCs) may allow accelerated and functional endothelialization of stents, theoretically reducing late stent complications as well reducing the duration of DAPT. In a pilot study of 193 patients at high risk of target vessel failure (TVF), the Genous EPC capturing stent (ESC) and TAXUS Liberté paclitaxel-eluting second-generation stent (PES) were similar at 5-years. Events rates appear higher for ESC within the first-year followed by higher rate of complications for PES during y...
We investigated the safety and efficacy of the bioabsorbable polymer-coated, everolimus-eluting coronary stent (SYNERGY) stent in a real-world study population with acute coronary syndromes (ACS).
Using optical coherence tomography, we evaluated early follow-up findings of significant stent malapposition (SSM) in patients treated with second-generation drug-eluting stent.
The MASTER study was designed to compare performance of a new biode-gradable polymer sirolimus-eluting stent (BP-SES) with a bare-metal stent (BMS) in patients with ST-segment elevation myocardial infarction (STEMI).
The aim of this study was to investigate whether the underlying plaque type affects the neointimal coverage after drug-eluting stent implantation.
Drug eluting stents are one of the main devices of coronary intervention, which play a therapeutic role through the combination of medical devices. Drug is an important part of the drug eluting stents. The loading method, the type of carrier, drug and carrier interaction and the preparation process of the drug directly affect the drugs release kinetics characteristics of the device and the final treatment. According to the characteristics of the drug coating, drug coated stents can be divided into non-degra...
It is unclear whether the obesity paradox is still apparent in the new-generation drug-eluting stent (DES) era. Therefore, we assessed the impact of body mass index (BMI) on clinical outcome after percutaneous coronary intervention (PCI) with new-generation DESs.
Drug-eluting stent (DES) strut fracture (SF) is associated with higher incidence of In-stent restenosis (ISR)-return of blockage in a diseased artery post stenting-than seen with bare metal stents (BMS). We hypothesize that concomitance of drug and SF leads to greater neointimal response.
Previous intravascular ultrasound studies suggested the association of stent underexpansion with increased risk of stent thrombosis and restenosis. However, no previous study has addressed the association of the suboptimal angiographic result with target-lesion revascularization (TLR) in patients receiving new-generation drug-eluting stents (DES).
The current guidelines from the European Society of Cardiology and European Society of Anaesthesiology on non-cardiac surgery (ESC/ESA-NCS) divide surgical procedures into those associated with low (5%) of major adverse cardiac events (MACE). Evaluating surgical risk might be particularly appropriate in patients with recent stent implantation and thus we validated the ESC/ESA-NCS classification in patients undergoing NCS within 1 year after coronary drug-eluting stent (DES) implantation.
Use of a BRS either in clinical practice or in the setting of an acute myocardial infarction (MI) is controversial. Despite an overall high rate of thrombosis, vascular healing response following BRS implantation tend to superiority as compared to metallic drug-eluting stent in ST-segment elevation myocardial infarction (STEMI) patients. We sought to compare the in-stent/scaffold vasomotion between metallic bioresorbable scaffold (BRS) and sirolimus eluting stent (SES) at 12-month angiographic follow-up in ...
Three-year Follow-up of the Randomized Comparison between Everolimus-eluting Bioresorbable Scaffold and Durable Polymer Everolimus-eluting Metallic Stent in Patients with ST-segment Elevation Myocardial Infarction (TROFI II Trial).
Intravascular ultrasound (IVUS)-guided drug-eluting stent (DES) implantation is associated with less major adverse cardiovascular events (MACE) compared with angiography guidance for patients with individual lesion subset. However, the beneficiary effect on MACE outcome of IVUS guidance over angiography guidance in all-comers who undergo DES implantation still remains understudied.
The goal of this analysis was to evaluate the final 5-year safety and effectiveness of the PROMUS Element platinum-chromium everolimus-eluting stent in unselected patients treated in routine clinical practice.
The aim of a drug eluting stent is to prevent restenosis of arteries following percutaneous balloon angioplasty. A long term goal of research in this area is to use modelling to optimise the design of these stents to maximise their efficiency. A key obstacle to implementing this is the lack of a mathematical model of the biology of restenosis. Here we investigate whether mathematical models of cancer biology can be adapted to model the biology of restenosis and the effect of drug elution. We show that relat...
Regulatory decisions approving new coronary drug-eluting stent (DES) require mechanistic observations of angiographic late lumen loss (LLL). Patient safety and device approval times could be enhanced if angiographic follow-up data were found to be generalizable across jurisdictions and geographies. The objectives were to assess the comparability of in-segment LLL in Eastern and Western DES populations using the world's largest compilation of follow-up quantitative coronary angiography data.
The authors sought to investigate the association between P2Y reaction units (PRU) and the risk of ischemic stroke (IS) after successful coronary drug-eluting stents (DES) implantation.
Prior numerical studies have shown that the blood flow patterns surrounding drug-eluting stents can enhance drug uptake in stented arteries. However, these studies employed steady-state simulations, wherein flow and drug transport parameters remained constant with respect to time. In the present study, numerical simulations and in-vitro experiments were performed to determine whether luminal blood flow patterns can truly enhance drug uptake in stented arteries. Unlike the aforementioned studies, the time-va...
This work aims to investigate the effects of plaque eccentricity and composition on the stent performance and stress distributions of plaque and artery during stenting by the finite element method. Three-dimensional stent-plaque-artery models for plaques with five different eccentricities and four different compositions were simulated, and the influences on stent recoil, stent plastic strain, stent foreshortening, stress distributions of artery and plaque, and lumen gain were studied. The results show that ...